West Pharmaceutical Services Inc
NYSE: WST · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
Updated 2026-04-29
West Pharmaceutical Services Inc (WST) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for WST.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
WST historical valuation range
Where current P/E sits in WST's own 5Y range.
WST intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
WST valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 39.05x
P/S Ratio — History
Current: 6.41x
Is WST overvalued in 2026?
West Pharmaceutical Services Inc (WST) currently trades at $295.36 per share with a market capitalization of $20,638,282,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 67/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 39.0x, below its 5-year median of 41.3x. The PEG ratio of 2.91 indicates the price has run ahead of the underlying growth rate.
Looking at its own history, WST is currently trading cheaper than 64% of the last 5Y on P/E. This places it in the 36th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates WST's intrinsic value at $184.38 per share, against the current market price of $295.36. This implies a premium to fair value of -33.51%. The current price sits well above what projected cash flows justify, implying investors are paying for growth that has not yet materialized.
The Piotroski F-Score of 5/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: WST trades at a fair valuation on our framework, with a Smart Value Score of 67/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is WST overvalued in 2026?
Based on a Smart Value Score of 67/100, WST is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is WST's fair value?
Our DCF model estimates WST's intrinsic value at $184.38 per share, versus the current price of $295.36. This produces a margin of safety of -33.51%.
What P/E ratio does WST trade at?
WST trades at a P/E of 39.0x on trailing twelve-month earnings, compared to its 5-year median of 41.3x.
Is WST a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 67/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does WST's valuation compare to its history?
On P/E, WST currently sits in the 36th percentile of its own 5Y range. That is below its long-run median relative to where it has traded over the period.
What is WST's Smart Value Score?
WST's Smart Value Score is 67/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.